Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs

Nigel Bourne, Fernando J. Bravo, Myriam Francotte, David I. Bernstein, Martin G. Myers, Moncef Slaoui, Lawrence R. Stanberry

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

In two recent clinical trials, a vaccine containing herpes simplex virus (HSV) type 2 glycoprotein D (gD2) and a novel adjuvant AS04 comprising alum (A1) and 3-deactylated monophosphoryl lipid A (3-dMPL) afforded HSV-seronegative women significant protection against HSV-2 genital disease (vaccine efficacy, 73% in study 1 and 74% in study 2) and limited protection against infection (46% in study 1 and 39% in study 2). In the present report, studies in the guinea pig model investigated the protection afforded by gD2/AS04 against HSV-1 and HSV-2 genital herpes and investigated whether immunization could prevent or reduce recurrent disease in guinea pigs that developed mucosal infection. Immunization with gD2/AS04 conveyed nearly complete protection against primary disease with either virus but did not prevent mucosal infection. Guinea pigs immunized with gD2/AS04 were significantly better protected against recurrent disease than were guinea pigs immunized with a gD2/Al vaccine, which suggests that inclusion of 3-dMPL improved protection against latent infection.

Original languageEnglish (US)
Pages (from-to)542-549
Number of pages8
JournalJournal of Infectious Diseases
Volume187
Issue number4
DOIs
StatePublished - Feb 15 2003

Fingerprint

Herpes Genitalis
Subunit Vaccines
Human Herpesvirus 2
Human Herpesvirus 1
Virus Diseases
Guinea Pigs
Vaccines
Infection
Immunization
Simplexvirus
Clinical Trials
Viruses
glycoprotein D-herpes simplex virus type 2
monophosphoryl lipid A

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. / Bourne, Nigel; Bravo, Fernando J.; Francotte, Myriam; Bernstein, David I.; Myers, Martin G.; Slaoui, Moncef; Stanberry, Lawrence R.

In: Journal of Infectious Diseases, Vol. 187, No. 4, 15.02.2003, p. 542-549.

Research output: Contribution to journalArticle

Bourne, Nigel ; Bravo, Fernando J. ; Francotte, Myriam ; Bernstein, David I. ; Myers, Martin G. ; Slaoui, Moncef ; Stanberry, Lawrence R. / Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. In: Journal of Infectious Diseases. 2003 ; Vol. 187, No. 4. pp. 542-549.
@article{0ceb8901e0f14d048dbfe562cdee454c,
title = "Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs",
abstract = "In two recent clinical trials, a vaccine containing herpes simplex virus (HSV) type 2 glycoprotein D (gD2) and a novel adjuvant AS04 comprising alum (A1) and 3-deactylated monophosphoryl lipid A (3-dMPL) afforded HSV-seronegative women significant protection against HSV-2 genital disease (vaccine efficacy, 73{\%} in study 1 and 74{\%} in study 2) and limited protection against infection (46{\%} in study 1 and 39{\%} in study 2). In the present report, studies in the guinea pig model investigated the protection afforded by gD2/AS04 against HSV-1 and HSV-2 genital herpes and investigated whether immunization could prevent or reduce recurrent disease in guinea pigs that developed mucosal infection. Immunization with gD2/AS04 conveyed nearly complete protection against primary disease with either virus but did not prevent mucosal infection. Guinea pigs immunized with gD2/AS04 were significantly better protected against recurrent disease than were guinea pigs immunized with a gD2/Al vaccine, which suggests that inclusion of 3-dMPL improved protection against latent infection.",
author = "Nigel Bourne and Bravo, {Fernando J.} and Myriam Francotte and Bernstein, {David I.} and Myers, {Martin G.} and Moncef Slaoui and Stanberry, {Lawrence R.}",
year = "2003",
month = "2",
day = "15",
doi = "10.1086/374002",
language = "English (US)",
volume = "187",
pages = "542--549",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs

AU - Bourne, Nigel

AU - Bravo, Fernando J.

AU - Francotte, Myriam

AU - Bernstein, David I.

AU - Myers, Martin G.

AU - Slaoui, Moncef

AU - Stanberry, Lawrence R.

PY - 2003/2/15

Y1 - 2003/2/15

N2 - In two recent clinical trials, a vaccine containing herpes simplex virus (HSV) type 2 glycoprotein D (gD2) and a novel adjuvant AS04 comprising alum (A1) and 3-deactylated monophosphoryl lipid A (3-dMPL) afforded HSV-seronegative women significant protection against HSV-2 genital disease (vaccine efficacy, 73% in study 1 and 74% in study 2) and limited protection against infection (46% in study 1 and 39% in study 2). In the present report, studies in the guinea pig model investigated the protection afforded by gD2/AS04 against HSV-1 and HSV-2 genital herpes and investigated whether immunization could prevent or reduce recurrent disease in guinea pigs that developed mucosal infection. Immunization with gD2/AS04 conveyed nearly complete protection against primary disease with either virus but did not prevent mucosal infection. Guinea pigs immunized with gD2/AS04 were significantly better protected against recurrent disease than were guinea pigs immunized with a gD2/Al vaccine, which suggests that inclusion of 3-dMPL improved protection against latent infection.

AB - In two recent clinical trials, a vaccine containing herpes simplex virus (HSV) type 2 glycoprotein D (gD2) and a novel adjuvant AS04 comprising alum (A1) and 3-deactylated monophosphoryl lipid A (3-dMPL) afforded HSV-seronegative women significant protection against HSV-2 genital disease (vaccine efficacy, 73% in study 1 and 74% in study 2) and limited protection against infection (46% in study 1 and 39% in study 2). In the present report, studies in the guinea pig model investigated the protection afforded by gD2/AS04 against HSV-1 and HSV-2 genital herpes and investigated whether immunization could prevent or reduce recurrent disease in guinea pigs that developed mucosal infection. Immunization with gD2/AS04 conveyed nearly complete protection against primary disease with either virus but did not prevent mucosal infection. Guinea pigs immunized with gD2/AS04 were significantly better protected against recurrent disease than were guinea pigs immunized with a gD2/Al vaccine, which suggests that inclusion of 3-dMPL improved protection against latent infection.

UR - http://www.scopus.com/inward/record.url?scp=0037442496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037442496&partnerID=8YFLogxK

U2 - 10.1086/374002

DO - 10.1086/374002

M3 - Article

VL - 187

SP - 542

EP - 549

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -